Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 10;10(6):e004762. doi: 10.1136/jitc-2022-004762

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

YST-OVH treatment inhibits tumor progression in humanized mice without induction of strong inflammatory responses, such as CRS. (A) Treatment scheme for a humanized mouse model. (B) Mice bearing Huh-7 tumors were intratumorally injected with vehicle, OVH or YST-OVH, and tumor growth was monitored over a 30-day period. Individual tumor growth curves of vehicle injected (C), OVH injected (D) and YST-OVH injected (E) tumors. Blood was collected at 0, 5 and 10 days after treatment for plasma cytokine analysis. (F) The IL-6 level was determined by ELISA assay. (G) The IFN-γ level was determined by ELISA assay. (H) The body weights of the experimental mice were recorded every 5 days. All values are presented as the mean±SEM; repeated-measure ANOVA (B), one-way ANOVA (F–H). ns, no significant differences; *p<0.05; OVH, oncolytic herpes simplex virus-1; YST-OVH, oncolytic herpes simplex virus-1 expressing PD-1 inhibitors; ANOVA, analysis of variance.